NuroTone Medical
Optical Cochlear Implant
Company Overview
Snapshot
Founded in September 2018 by Yossi Bornstein, Danny Albeck, and Prof. Claus Richter, NuroTone Medical operates with 1–10 employees. The company is currently in the Pre-Funding stage and ceased operations in December 2025.
Business overview
NuroTone Medical is a Health Tech & Life Sciences company focused on developing advanced medical devices. The company's core product is an optical cochlear implant designed to overcome the limitations of existing cochlear implant technology. By utilizing precise laser stimulation of cochlear neurons, NuroTone aims to enhance speech recognition and music perception, reduce sensitivity to environmental noise, and decrease the effort required for daily hearing and training. NuroTone operates in the medical technologies sector, targeting global markets with its B2B business model.
Log in to access full profile ›Company Intelligence Q&A
- What is NuroTone Medical's primary focus?
- NuroTone Medical is developing an optical cochlear implant that uses precise light stimulation of cochlear neurons to improve hearing capabilities beyond traditional cochlear implant technology.
- When was NuroTone Medical founded?
- NuroTone Medical was founded in September 2018.
- Who are the founders of NuroTone Medical?
- The company was founded by Yossi Bornstein, Danny Albeck, and Prof. Claus Richter.
- What is the current operational status of NuroTone Medical?
- NuroTone Medical ceased to operate in December 2025.
- What problem does NuroTone Medical aim to solve with its technology?
- NuroTone Medical aims to improve speech recognition and music perception, reduce sensitivity to environmental noise, and decrease the effort of daily hearing for individuals with hearing impairments, addressing the inherent limitations of existing cochlear implant technology.